Expression of SLC25A48 in Chronic Obstructive Pulmonary Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFu Jen Catholic University
About this trial
This study aims to investigate the expression level of SLC25A48, a mitochondrial choline transporter, in peripheral blood mononuclear cells of patients with chronic obstructive pulmonary disease, and to analyze its correlation with inflammatory markers and choline metabolic byproducts.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
pre-COPD or COPD stages I-IV as per the 2023 GOLD guidelines (case group)
healthy individuals without chronic diseases or major medical conditions
Disqualifiers
diagnosed with neuromuscular diseases
experienced respiratory disease exacerbation requiring emergency care or hospitalization in the past three months
assessed by a physician to have severe malnutrition or a significantly low BMI
continuously taking folic acid supplements
Trial population
patient of hospital
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
180 Participants
are grouped into 2 trial groupsGroup A: Case group
Group B: Control group
Trial outcomes
Primary outcomes
1
expression of SLC25A48
the expression level of SLC25A48 in mitochondria isolated from peripheral blood mononuclear cells
Time frame
one daySponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov